title: [Probiotics as an items of increasing the effectiveness of treatment of community-acquired pneumonia in adolescents].
abstract: The aim of the work was to evaluate the efficiency of microbial probiotics Vitaflor and metabolic probiotic Aktoflor-C in complex treatment of community-acquired pneumonia in adolescents in a hospital. The observation involved 38 children aged 11 to 18 years with radiologically verified community-acquired pneumonia, including 23 boys and 15 girls. Patients were divided in 3 groups. Patients in group 1 (n = 13) simultaneously with the antibiotic therapy received per os Vitaflor probiotic containing symbiotic strains of Lactobacillus acidophilus; patients in group 2 (n = 10) along with antibiotic therapy received per os metabolic probiotic Aktoflor-C, containing low molecular weight exometabolites bacteria; patient of the comparison group (n = 15) received antibiotic therapy only. The effectiveness of the used treatment schemes was assessed on the dynamics of the gut state microbiot acoarding to an extended bacteriological examination of faecal flora, level of saliva IgA secretory (before and after treatment), the dynamics of SF-36 quality of life 1 month after discharge from hospital. Was conducted a study of economic efficiency of different modes of therapy. Results showed that adolescents with community-acquired pneumonia during standard antibiotic therapy indicated development of dysbiotic bowel disturbances in the form of reliable oppression of the bifidobacteria and laktoflora. Dysbiosis of the microbial associations are not conducive to proper implementation of immune and nutritional functions of the intestine that shows the imperfection of rehabilitation of patients with pneumonia according to the evaluation of SF-36 quality of life. Pharmacoeconomic analysis revealed the benefits of probiotic metabolic type "Aktoflor" used in addition to standard therapy of community-acquired pneumonia in adolescents.
authors.forename: N V
authors.initials: NV
authors.lastname: Gonchar
authors.forename: L N
authors.initials: LN
authors.lastname: Kassner
authors.forename: P B
authors.initials: PB
authors.lastname: Korenev
authors.forename: Iu M
authors.initials: IuM
authors.lastname: Il'kovich
authors.forename: S V
authors.initials: SV
authors.lastname: Mogilina
authors.forename: L N
authors.initials: LN
authors.lastname: Petrov
mesh_terms: D000293:Adolescent; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D002648:Child; D003141:Communicable Diseases / Q000628:therapy*; D005260:Female; D006801:Humans; D007779:Lactobacillus acidophilus; D008297:Male; D011014:Pneumonia / Q000628:therapy*; D019936:Probiotics / Q000008:administration & dosage*
chemical_list: D000900:Anti-Bacterial Agents